Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

11161. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival

Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2003 DARE.

11162. Communication, information and support for adults with malignant cerebral glioma: a systematic literature review

of support such as counselling. Studies that investigate the impact of cognitive differences in the comprehension of information would be useful to inform practice. Bibliographic details Davies E, Higginson I J. Communication, information and support for adults with malignant cerebral glioma: a systematic literature review. Supportive Care in Cancer 2003; 11(1): 21-29 PubMedID DOI Indexing Status Subject indexing assigned by NLM MeSH Adult; Aged; Awareness; Brain Neoplasms /psychology /therapy (...) by which cancer patients are cared for should be applied to patients with cerebral glioma. This conclusion may not be reliable because all included studies were observational and no evidence of effective interventions was found. Authors' objectives To establish the evidence for information, communication and support for adults with malignant cerebral glioma. Searching MEDLINE (1966 to May 2000), EMBASE (1988 to May 2000), CINAHL (1982 to March 2000), British Nursing Index (March 2000), Cancerlit

2003 DARE.

11163. Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors

Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors Delgado-Bolton R C, Fernandez-Perez C, Gonzalez-Mate A, Carreras J L CRD summary This review aimed to determine the usefulness of 18-fluorine fluorodeoxyglucose positron emission tomography (18F (...) -FDG PET) in detecting primary tumours whose location is unknown. It concluded that 18F-FDG PET may be useful for this purpose and would miss few tumours that subsequently prove locatable by other available tests. However, further research is required to determine the effect of this imaging technique on patient management. Authors' objectives To assess the accuracy of 18-fluorine fluorodeoxyglucose positron emission tomography (18F-FDG PET) for the detection of primary tumours in patients

2003 DARE.

11164. Invasive staging of non-small cell lung cancer: a review of the current evidence

-positive and true-negative results summed across the studies. Studies in which all participants had mediastinol disease were excluded from these calculations. The data were analysed in three ways: for patients undergoing invasive techniques (regardless of the indication), where a definitive diagnosis of any malignancy was considered positive and a definitive benign diagnosis was considered negative; for patients suspected of having lung cancer (either non-SCLC or SCLC), where a definitive diagnosis (...) for practice or further research. Funding American College of Chest Physicians. Bibliographic details Toloza EM, Harpole L, Detterbeck F, McCrory DC. Invasive staging of non-small cell lung cancer: a review of the current evidence. Chest 2003; 123(1 Supplement): 157S-166S PubMedID DOI Original Paper URL Indexing Status Subject indexing assigned by NLM MeSH Biopsy, Needle; Carcinoma, Non-Small-Cell Lung /diagnosis /pathology /secondary; Endosonography; Evidence-Based Medicine; Humans; Lung Neoplasms

2003 DARE.

11165. Noninvasive staging of non-small cell lung cancer: a review of the current evidence Full Text available with Trip Pro

was to evaluate the accuracy of clinical evaluation for predicting metastatic disease in suspected lung cancer patients. Searching MEDLINE (from January 1991 to July 2001), HealthSTAR and the Cochrane Library. The keywords used were reported. In addition, the authors searched the reference lists from a number of sources. Only English language articles were included. Study selection Study designs of evaluations included in the review Inclusion and exclusion were not reported in terms of the study design (...) . The studies had to include at least 20 patients, while studies of CT scanning had to include at least 50 patients. Specific interventions included in the review Question 1: studies that examined CT scanning, MRI, EUS and PET scanning for detecting malignant mediastinal lymph node involvement were eligible. Question 2: studies that examined the accuracy of clinical evaluation for predicting metastatic disease were eligible. Reference standard test against which the new test was compared Question 1

2003 DARE.

11166. Prevention of lung cancer: summary of published evidence

. The primary prevention studies included smokers and non-smokers; the tertiary prevention studies included patients with head and neck and/or lung cancer. Outcomes assessed in the review The outcome eligible for inclusion was lung cancer incidence. In the tertiary prevention studies this was defined as a second primary tumour. How were decisions on the relevance of primary studies made? The authors did not state how the papers were selected for the review, or how many reviewers performed the selection (...) Prevention of lung cancer: summary of published evidence Prevention of lung cancer: summary of published evidence Prevention of lung cancer: summary of published evidence Kelley MJ, McCrory DC CRD summary This review assessed the effect of chemoprevention on the incidence of lung cancer. The authors concluded that no agent has been shown to be effective in preventing lung cancer. The conclusions are in line with the evidence presented but may not be reliable because validity of included studies

2003 DARE.

11167. The efficacy of behavioral interventions for cancer treatment-related side effects

chemotherapy, surgery, or radiotherapy. Most of the included studies contained people with many different types of cancer, and they were of children and adults. Details about the gender and disease of the participants from each study were tabulated in the review. Outcomes assessed in the review Studies were eligible if they included data about any cancer treatment-related adverse effect, such as pain, nausea and vomiting, and anxiety and distress. How were decisions on the relevance of primary studies made (...) The efficacy of behavioral interventions for cancer treatment-related side effects The efficacy of behavioral interventions for cancer treatment-related side effects The efficacy of behavioral interventions for cancer treatment-related side effects Mundy E A, DuHamel K N, Montgomery G H CRD summary This review found that behavioural interventions could reduce anticipatory nausea and vomiting in people undergoing chemotherapy and decrease anxiety related to cancer diagnosis and treatment

2003 DARE.

11168. Docetaxel in advanced gastric cancer: review of the main clinical trials

Docetaxel in advanced gastric cancer: review of the main clinical trials Docetaxel in advanced gastric cancer: review of the main clinical trials Docetaxel in advanced gastric cancer: review of the main clinical trials Di Cosimo S, Ferretti G, Fazio N, Silvestris N, Carlini P, Alimonti A, Gelibter A, Felici A, Papaldo P, Cognetti F CRD summary This review assessed the effectiveness of docetaxel, either as a single agent or in combination with other widely used cancer drugs, in the treatment (...) of advanced gastric cancer. The authors concluded that firm conclusions about the effectiveness of docetaxel cannot be drawn until the results of further phase III studies are available. On the basis of the limited evidence reviewed and a number of potential biases in the review process, this statement appears reliable. Authors' objectives To assess the effectiveness of docetaxel, either as a single agent or in combination with widely used other cancer drugs, in the treatment of advanced gastric cancer

2003 DARE.

11169. Meta-analysis of the effect of psychoeducational interventions on pain in adults with cancer

Meta-analysis of the effect of psychoeducational interventions on pain in adults with cancer Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2003 DARE.

11170. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer

Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2003 DARE.

11171. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C

to define whether a screening strategy can provide clinically important benefits. Funding PRIME Residency Program, University of California. Bibliographic details Gupta S, Bent S, Kohlwes J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. Annals of Internal Medicine 2003; 139(1): 46-50 PubMedID Original Paper URL Indexing Status Subject indexing assigned by NLM MeSH Biomarkers, Tumor /blood; Carcinoma, Hepatocellular /complications (...) Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C Gupta S, Bent S, Kohlwes J CRD summary This review evaluated the accuracy of alpha-foetoprotein (AFP) for the diagnosis of hepatocellular carcinoma (HCC) in patients

2003 DARE.

11172. Use of adjuvant chemotherapy following cystectomy in patients with deep muscle-invasive transitional cell carcinoma of the bladder

Use of adjuvant chemotherapy following cystectomy in patients with deep muscle-invasive transitional cell carcinoma of the bladder Use of adjuvant chemotherapy following cystectomy in patients with deep muscle-invasive transitional cell carcinoma of the bladder Use of adjuvant chemotherapy following cystectomy in patients with deep muscle-invasive transitional cell carcinoma of the bladder Segal R, Winquist E, Lukka H, Chin J, Brundage M, Markman B, Genitourinary Cancer Disease Site Group CRD (...) patient for whom adjuvant chemotherapy is being considered. The use of a cisplatin-based combination chemotherapy regimen from one of the identified RCTs is recommended if chemotherapy is opted for. Research: The authors did not state any implications for future research. Funding Cancer Care Ontario; Ontario Ministry of Health and Long-term Care. Bibliographic details Segal R, Winquist E, Lukka H, Chin J, Brundage M, Markman B, Genitourinary Cancer Disease Site Group. Use of adjuvant chemotherapy

2003 DARE.

11173. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis

. Around 85% of the participants in the included studies were male and 80% were aged 55 years or older. Details of T category, N category and grade of disease were given in the review together with details of performance status, tumour diameter and renal function. Outcomes assessed in the review The primary outcome was overall survival, defined as time from randomisation to death. Death was all-cause. Living patients were censored on date of last follow-up. The secondary outcomes were disease-free (...) Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis Parmar M K, Stewart L A, Tierney J F, Vale C L CRD summary This was a well-conducted meta-analysis of patient level data on the effect of neoadjuvant chemotherapy on survival in invasive bladder cancer. The findings showed

2003 DARE.

11174. Cervical cancer and use of hormonal contraceptives: a systematic review

cervical cancer, carcinoma in situ, or cervical intraepithelial neoplasia (CIN) grade 3. The studies also had to include data on the number of participants and present age-adjusted or age-matched relative risks (RRs) or odds ratios and their corresponding 95% confidence intervals (CIs). How were decisions on the relevance of primary studies made? The authors did not state how the papers were selected for the review, or how many reviewers performed the selection. Assessment of study quality The authors (...) were also observed for invasive and in situ cancers, for squamous and adenocarcinoma, and for studies adjusted for HPV status, number of sexual partners, cervical screening, smoking and use of barrier contraceptives. For medium- and long-term users (at least 5 years), the risks were lower for women who had ceased oral contraceptive use at least 8 years ago (RR 1.4, 95% CI: 1.1, 1.9) than those who ceased less than 8 years ago (RR 2.1, 95% CI: 1.8, 2.4); similar but smaller effects were found

2003 DARE.

11175. The role of erythropoietin in the management of cancer patients with non-hematologic malignancies receiving chemotherapy

The role of erythropoietin in the management of cancer patients with non-hematologic malignancies receiving chemotherapy The role of erythropoietin in the management of cancer patients with non-hematologic malignancies receiving chemotherapy The role of erythropoietin in the management of cancer patients with non-hematologic malignancies receiving chemotherapy Quirt I, Bramwell V, Charette M, Oliver T, Systemic Treatment Disease Site Group CRD summary The data presented in this review support (...) no greater than 100 g/L during the initial courses of myelosuppressive cancer chemotherapy or haemoglobin levels no greater than 120 g/L with symptoms of anaemia affecting functional capacity or quality of life; and anaemia related directly or indirectly to malignancy, but not caused by haemolysis, gastrointestinal bleeding, or iron or folate deficiencies. The included studies comprised both children and adults. The tumours types included gynaecological, bone, solid, and multiple types. Studies were

2003 DARE.

11176. A systematic review and lessons learned from early lung cancer detection trials using low-dose computed tomography of the chest

of detected lung cancers: the CT screening trials predominantly detected adenocarcinoma (80%). Only 12% of squamous cell carcinoma and 8% of other subtypes were reported. Detection rate of suspicious abnormalities (noncalcified pulmonary nodules): the rate for noncalcified pulmonary nodules ranged from 5 to 51%, with the smallest detectable lesions below 3 mm. The positive predictive values (proportion of lung cancers among those with suspicious lesions) of CT scanning for lung cancer was variable (0.02 (...) detected more lung cancers: 27 and 13 for CT versus 7 and 5, respectively, for chest radiography. Stage of cancer at detection: in the CT screening studies, there were 119 stage I or II lung cancer cases, and 18 stage III or IV lung cancer cases (including small-cell lung cancer cases). Lung cancer mortality and overall mortality: the data on disease-specific and overall mortality were incomplete. Screening-related morbidity and mortality: no screening-related deaths were reported. Histology

2003 DARE.

11177. Economic evaluation of breast cancer treatment: considering the value of patient choice

calculations were not reported. Eligible patients were identified from a 5% random sample of all Medicare claims for patients with a breast cancer diagnosis or surgery procedure, for the calendar years 1992 to 1994. Women with a history of cancer diagnosis, carcinoma-in-situ diagnosis, metastasis diagnosis, or bilateral procedure were excluded. Also excluded were cases that lacked a surgical procedure core, were missing a physician identifier, or occurred in women younger than 67 years of age. Further (...) Economic evaluation of breast cancer treatment: considering the value of patient choice Economic evaluation of breast cancer treatment: considering the value of patient choice Economic evaluation of breast cancer treatment: considering the value of patient choice Polsky D, Mandelblatt J S, Weeks J C, Venditti L, Hwang Y T, Glick H A, Hadley J, Schulman K A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains

2003 NHS Economic Evaluation Database.

11178. The cost-effectiveness of low-dose CT screening for lung cancer: preliminary results of baseline screening

of Medicine 1982;73:889-97. Indexing Status Subject indexing assigned by NLM MeSH Carcinoma, Non-Small-Cell Lung /diagnosis /mortality /pathology; Cost-Benefit Analysis; Dose-Response Relationship, Radiation; Humans; Lung Neoplasms /diagnosis /mortality /pathology; Mass Screening /economics; Middle Aged; Prevalence; SEER Program; Smoking /adverse effects; Tomography, X-Ray Computed /economics AccessionNumber 22003001127 Date bibliographic record published 31/08/2004 Date abstract record published 31/08 (...) The cost-effectiveness of low-dose CT screening for lung cancer: preliminary results of baseline screening The cost-effectiveness of low-dose CT screening for lung cancer: preliminary results of baseline screening The cost-effectiveness of low-dose CT screening for lung cancer: preliminary results of baseline screening Wisnivesky J P, Mushlin A I, Sicherman N, Henschke C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each

2003 NHS Economic Evaluation Database.

11179. Cancer-attributable costs of diagnosis and care for persons with screen-detected versus symptom-detected colorectal cancer

(92.8%). A total of 480 (32.6%) patients did not meet study eligibility criteria or were unavailable for analysis. Patients excluded were those enrolled in the HMO for less than a year before diagnosis, and those with a known history of colon polyps, ulcerative colitis, Crohns disease or familial polyposis syndrome. Also excluded were those patients whose cancer was detected following screening endoscopy or an FOBT performed in their physician's office. Study design This was a retrospective cohort (...) study performed in an HMO setting, serving a population of 450,000, with a 7-year follow-up period. Analysis of effectiveness The primary health outcomes used in the analysis were cancer stage at diagnosis, incidence, survival and mortality rates. In addition, a chronic disease score (CDS) was used for all patients and in both groups to compare non-cancer co-morbidity at the time of diagnosis. The CDS is associated with physician-rated disease severity and patient-rated health status. It predicts

2003 NHS Economic Evaluation Database.

11180. An economic viewpoint on alternative strategies for identifying persons with hereditary nonpolyposis colorectal cancer Full Text available with Trip Pro

of the disease, followed by mutation analysis for those with MSI high tumours. Strategy 2 involved MSI testing for all individuals, irrespective of family or personal history. For both strategies 1 and 2, persons found to have MSI high tumours were offered DNA testing for mismatch repair (MMR) mutations. Strategy 3 involved DNA MMR mutation testing for those who satisfied the conditions regarding clinical and family history outlined in the Bethesda guidelines). Strategy 4 entailed all individuals undergoing (...) cancer. Genetics in Medicine 2003; 5(5): 353-336 PubMedID DOI Indexing Status Subject indexing assigned by NLM MeSH Colorectal Neoplasms, Hereditary Nonpolyposis /diagnosis; DNA Mutational Analysis /economics; Genetic Testing /economics; Humans; Microsatellite Repeats AccessionNumber 22003009942 Date bibliographic record published 30/11/2004 Date abstract record published 30/11/2004 NHS Economic Evaluation Database (NHS EED) Produced by the Centre for Reviews and Dissemination Copyright © 2019

2003 NHS Economic Evaluation Database.